FDA launches new priority review voucher program for select biopharmas

Gilenya

Kidney urine lupus
Research

Novartis' MS drug Gilenya could inspire new CKD treatment

Scientists at the University of Virginia found that targeting a cellular transporter of S1P might be a viable strategy for chronic kidney disease.
Angus Liu Aug 18, 2022 4:55pm
Celgene

Safety profile 'will help bring ozanimod to MS market'

May 26, 2017 8:42am